DDInter596 DDInter1105
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Doxorubicin {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Doxorubicin (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Doxorubicin (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Lurbinectedin